A model for the investigation of factors influencing haemorrhagic necrosis mediated by tumour necrosis factor in tissue sites primed with mycobacterial antigen preparations
Open Access
- 28 June 1992
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 88 (3) , 537-542
- https://doi.org/10.1111/j.1365-2249.1992.tb06483.x
Abstract
SUMMARY: Mycobacterial lesions and skin sites challenged with soluble mycobacterial antigen are very sensitive to the necrotizing effect of tumour necrosis factor (TNF). We have used a model that permits separate quantitative assessment of swelling and haemorrhage to show that when these reactions are elicited in mice that have not been deliberately immunized, pretreatment of the mice with lipopolysaccharide (LPS), or with a MoAb to CR3 which blocks emigration of myeloid cells into the tissues, will block both the swelling and the haemorrhage. On the other hand, treatment with an inhibitor of platelet-activating factor (PAF), or with misoprostol (a synthetic prostaglandin E1 analogue), or with cobra venom factor (CVF) which depletes complement, preferentially blocks the haemorrhagic component, while leaving the swelling relatively unaltered. As swelling occurs before the haemorrhage is seen, it is possible that these factors act at a late stage in the cascade of events leading to the tissue damage. However, LPS and CVF were able to inhibit swelling and haemorrhage in the massive reactions elicited in pre-immunized animals, whereas the PAF inhibitor had no detectable effect.Keywords
This publication has 23 references indexed in Scilit:
- Cytokines and the Koch phenomenonTubercle, 1991
- Hydrazine sulfate protects D-galactosamine-sensitized mice against endotoxin and tumor necrosis factor/cachectin lethality: evidence of a role for the pituitary.The Journal of Experimental Medicine, 1991
- TUMOUR NECROSIS FACTOR IN BRONCHOPULMONARY SECRETIONS OF PATIENTS WITH ADULT RESPIRATORY DISTRESS SYNDROMEPublished by Elsevier ,1989
- Exacerbation of murine listeriosis by a monoclonal antibody specific for the type 3 complement receptor of myelomonocytic cells. Absence of monocytes at infective foci allows Listeria to multiply in nonphagocytic cells.The Journal of Experimental Medicine, 1989
- The therapeutic value of vasodilator prostaglandins in multiple organ failure associated with sepsisIntensive Care Medicine, 1988
- Tumor necrosis factor/cachectin. Induction of hemorrhagic necrosis in normal tissue requires the fifth component of complement (C5).The Journal of Experimental Medicine, 1988
- The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity.The Journal of Experimental Medicine, 1988
- Protective effect of WEB 2086, a novel antagonist of platelet activating factor, in endotoxin shockEuropean Journal of Pharmacology, 1987
- Is platelet activating factor (PAF) a mediator of endotoxin shock?European Journal of Pharmacology, 1985
- Multiple skin testing of tuberculosis patients with a range of new tuberculins, and a comparison with leprosy andMycobacterium ulceransinfectionEpidemiology and Infection, 1977